

Review article

Role of Interleukin-8 in *Helicobacter pylori* induced gastric cancer: Targeting IL-8 can have a potential antitumor effect.

Ritu Saha¹

¹Dr. Ritu Saha, Associate Professor, Department of Microbiology, Bashundhara Ad-din Medical College

Correspondence: Dr. Ritu Saha, Associate Professor, Department of Microbiology, Bashundhara Ad-din Medical College

How to cite this article: Saha R. Role of Interleukin-8 in *Helicobacter pylori* induced gastric cancer: Targeting IL-8 can have a potential antitumor effect. Ad-din Med J. 2023 Jul;1(1):26-30.

Copyright: This article is published under the Creative Commons CC By-NC License  (<https://creativecommons.org/licenses/by-nc/4.0>). This license permits use, distribution and reproduction in any medium, provided the original work is properly cited, and is not used for commercial purposes.

Introduction:

Helicobacter pylori is a spiral-shaped Gram negative bacteria that is specialized in colonizing the human gastric mucosa, where it causes a variety of clinical outcomes ranging from asymptomatic carriage to gastritis, peptic ulcers, and cancer.¹ Since *H. pylori* is a noninvasive bacterium, it has been assumed that trans-epithelial signal transmission must be involved in initiating the inflammatory response in *H. pylori*-associated gastritis.² Of the many cytokines that can be induced by a bacterial infection followed by the pathologic changes seen in inflammation; chemokines are possible candidates to act as a signal following the contact of bacteria with the epithelium.^{3,4} An important cytokine that plays a central role in the pathogenesis of *H. pylori*-induced diseases is Interleukin 8. It is a potent chemoattractant for neutrophils and lymphocytes. It also has effects on cell proliferation, migration, and tumor angiogenesis.⁵

Genetic factors like cytokine gene polymorphism is also responsible for the pathogenesis and severity of gastroduodenal disease. The IL-8 gene has a well-established promoter polymorphism at position -251 (IL-8-251 Thymine/Adenine). The A allele is associated with increased production of IL-8 in *H. pylori*-infected gastric mucosa. It was also found to increase the risk of severe inflammation and precancerous gastric abnormalities in white and Asian populations.^{6,7}

IL-8 polymorphisms may increase the risk of gastric cancer. Taguchi et al reported the association of the IL-8-251 A/T polymorphism with higher expression of IL-8 protein, severe neutrophil infiltration and higher risk of atrophic gastritis and gastric cancer.⁶

Role of IL-8 in developing *H. pylori* induced gastric cancer:

IL-8 seems to have significant potential as a prognostic and predictive cancer biomarker. IL-8 was originally identified as a chemoattractant for neutrophils that release some growth factors that promote angiogenesis as a part of cancer progression. The roles for IL-8 in the angiogenesis of gastric cancer have drawn much interest. Since invasion and angiogenesis are all involved in the metastatic process, IL-8 expression in gastric cancer can influence their metastatic capabilities. Upregulation of IL-8 in human gastric carcinomas correlates closely with their angiogenesis. In contrast, inhibition of IL-8 decreases angiogenesis in gastric cancer.⁸

The downstream signals of IL-8 produced by *H. pylori* have been intensively studied. All biological effects of IL-8 are mediated by two receptors designated CXCR1 and CXCR2. It binds with high specificity to CXCR1 and with less specificity to CXCR2 expressed on stromal, endothelial and tumor cells. IL-8 stimulates vascular endothelial growth factor (VEGF) expression in endothelial cells via CXCR-2 and thereby promotes the activation of VEGF receptors in an autocrine fashion.⁹ IL-8 has also been linked with cell adhesion and migration in gastric cancer. IL-8 activates NF- κ B and Akt signals and induces adhesion molecules including intercellular adhesion molecule- 1 (ICAM-1), vascular cell adhesion molecule-1 and CD44 expression in gastric cancer cells.¹⁰




Figure 1: Roles for interleukin-8 in tumor progression and metastasis.¹¹

(EMT: Epithelial-mesenchymal transition; IL-8: Interleukin-8.)

Although it is well known that *H. pylori* enhances IL-8 expression in gastric cancer cells, the molecular mechanism of the underlying fact is not fully understood. Genomic structure analysis of IL-8 showed many potential targets for both transcriptional and post-transcriptional regulation. Within its 3'-flanking region, the IL-8 gene contains a repetitive ATTTA motif, which destabilize various cytokine mRNAs. Within the 5'-flanking region, the gene contains multiple cis elements including a CCAAT box, steroid-responsive factors, interferon regulatory factor-1, hepatocyte nuclear factor-1, binding sites for activator protein-1 (AP-1), CCAAT/enhancer binding protein and NF-κB. These stimulations can induce *IL-8* gene transcription.^{13,14}

Mutation and deletion analyses demonstrated that, these promoter elements are regulated in cell type-specific manners. A cascade of intracellular signals mediates the effects of *H. pylori* including production of reactive oxygen species (ROS), and activation of transcription factor NF-κB, AP-1 and mitogen-activated protein kinase (MAPK).¹⁴ ROS plays pivotal role in the pathogenesis of *H. pylori*-associated gastric diseases that include gastric cancer.¹⁵

Signals involved in *H. pylori*-induced IL-8 in Gastric Cancer

After exposure to *H. pylori* a whole genome analysis of the epithelial response revealed *IL-8* as the most markedly upregulated gene. IL-8 play a significant role in the epithelial cell response to *H. pylori* infection and in the pathological processes leading to gastroduodenal disease.

IL-8 induction in gastric epithelial cells are correlated with a functional *cagA* gene.¹⁶ In *vitro* examinations of *H. pylori* infection of gastric epithelial cells showed that, the proteins encoded by the *cagPAI* are required for IL-8 secretion and the regulation of IL-8 induction by the NF-κB pathway.^{17,18}

ROS induce apoptotic cell death of *H. pylori*-infected gastric epithelial cells and produced by NADPH oxidase (NOX1). NOX1 produce superoxide anion and hydrogen peroxide. 13ROS also activates MAPKs, such as extracellular signal-related kinases (ERKs), c-Jun NH2-terminal kinases (JNKs) and p38 MAPK, and enhances transcription of NF-κB. Increased expression of NOX1 mRNA provokes the generation of superoxide anion, which is indicative of oxidative stress. Interestingly, IL-8 contributes to the generation of copious quantities of ROS, and induction of IL-1β, IL-6, IL-8, IL-12, tumor necrosis factor-alpha, and interferon-gamma.¹⁹

IL-8 activates the CD11b/CD18 dimer that can make a complex with neutrophils. This complex activates ICAM-1 on the vascular endothelial cell membrane. Infiltration of this tetramer (CD11b/CD18/ neutrophil/ICAM-1) in gastric epithelial cells facilitates the copious release of ROS through neutrophil NADPH oxidase. Ultimately an oxidative burst occurs. The ROS released from gastric epithelial cells mediate the chemoattractant function of neutrophils and monocytes in *H. pylori*-infected gastric tissues.^{20,21,12}

H. pylori can activate the transcription factor AP-1 like cagPAI. The AP-1 complex activated during *H. pylori* infection is composed of c-jun and c-fos heterodimers. AP-1 is activated by MAPK. It can induce potential pro-inflammatory response, often in concert with NF- κ B.²²

H. pylori can activate MAPKs when they come in contact with gastric epithelial cells. MAPK cascades are well characterized pathways that cause signal transduction from the cell surface to the nucleus. This family includes following subgroups: ERKs, JNKs and p38 MAPK. Some bacterial factors including vacA and cagA can also activate MAPK. JNK activation during *H. pylori* infection also requires a functional T4SS.²²

Peptidoglycan of *H. pylori* is delivered to the host cell via the T4SS, where cytosolic nucleotide binding and oligomerization domain 1 (NOD1) recognize it.¹⁵




Figure 2: Scheme of signaling of *Helicobacter pylori*-induced interleukin-8 in gastric cancer cells.¹¹

[PI3-K: Phosphoinositide 3-kinase; HSP: Heat shock protein; TLR: Toll-like receptor; NOX: NADPH oxidase; NOD: Nucleotide binding and oligomerization domain; IKK: I κ B kinase; ROS: Reactive oxygen species; RICK: Receptor- interacting protein serine-threonine kinase; MAPK: Mitogen-activated protein kinase; NF- κ B: Nuclear factor kappa B; AP-1: Activator protein-1.]

NOD1 with the receptor-interacting protein serine-threonine kinase 2 can trigger a pro-inflammatory response upon stimulation with purified agonist. This response is characterized by NF- κ B activation and IL-8 production. In addition to activation of the classical NF- κ B pathway, NOD1 is required for activation of MAPK in response to bacterial infection. This NOD1-dependent p38 MAPK activation enhances IL-8 production.^{23,24} Understanding the signals involved in IL-8 expression by *H. pylori* may be beneficial to develop new therapeutics in gastric cancer.¹³

IL-8 as a Therapeutic Target in Gastric Cancer:

Increased IL-8 expression in gastric cancer suggests that IL-8 might be a potential therapeutic target to prevent progression of cancer. Prevention of *H. pylori*-induced IL-8 expression and regulation of the IL-8 downstream signals can be achieved by many proposed inhibitors. IL-8 induction by *H. pylori* can be inhibited by polyphenols derived from natural products that include resveratrol, apigenin and anthocyanins. Resveratrol suppresses the secretion of IL-8 from *H. pylori*-infected gastric epithelial cells. It reduces ROS, inhibits MAPK, AP-1 and NF- κ B.²⁵

Resveratrol may inhibit the expression of IL-8 by modulation of regulatory enzymes like MAPK. Anti-oxidant anthocyanins from black soybean may inhibit IL-8 production. Anthocyanins contain abundant of Cyanidin- 3-glucoside, which is an effective anti-oxidant. It inactivates NF- κ B by inhibiting phosphorylation of I κ B.¹⁵ Apigenin also inhibits NF- κ B by increasing the I κ B α .²⁶

Phenyl-thiophenyl propenone RK-I-123 is a small molecule that suppresses the activation of NF- κ B and AP-1, reduces the level of ROS and expression of IL-8 in *H. pylori*-infected gastric epithelial cells.²⁷

7-Carboxymethoxy-3',4',5-trimethoxy flavone (DA-6034) is a synthetic derivative of eupatilin that may reduce the level of IL-8 induction by *H. pylori*.²⁸

Rebamipide [2-[4-chlorobenzoylamino]-3-[2[1H] quinolin-4-yl]; OPC-12759], is a mucosal protective anti-ulcer agent; is a propionic acid derivative. It was reported to inhibit IL-8 in gastric cancer by the regulation of phospholipase D (PLD) expression.²⁹ Gefitinib (Iressa™, ZD1839) is an orally active quinazoline-derived agent that inhibits EGF receptor (EGFR)-tyrosine kinase thus downregulate epidermal growth factor (EGF) signals and IL-8 production in gastric cancer cells.³⁰

Surprisingly some scientists observe that IL-8 production induced by *H. pylori*-activated Toll-like receptor 4 (TLR4) may be inhibited by application of probiotic, such as lactobacilli. *Lactobacillus bulgaricus* (LBG) is used in the production of yogurt, which is one of the best-studied probiotic microbes. Activation of NF- κ B and IL-8 expression in *H. pylori*-infected gastric epithelial cells is also inhibited by conjugated linoleic acids (CLA) produced by *Lactobacillus acidophilus* (LBA).³¹

IL-8 gene expression is regulated by several microRNAs (miR); which are central regulators of several physiological processes. So, disruption of miR is associated with human diseases. Some studies suggested that miR-146a negatively regulated *H. pylori* induced IL-8 via reduced NF- κ B activity.³²

In a nutshell, the above mentioned discussion on the basis of a large number of published articles suggest that, IL-8 can be a potential target in *H. pylori* induced gastric cancer and have large spectrum of antitumor effect. Anti-IL-8 anticancer therapy are yet to enter in clinical trials; so, further clinical experiment based studies can open a window in the treatment of *H. pylori* induced gastric carcinoma.

References:

1. Backhead F, Torstensson E, Seguin D, Richter-dahlfors A, Rokbi B. Helicobacter pylori Infection Induces Interleukin-8 Receptor Expression in the Human Gastric Epithelium. *Infection and Immunity*. 2003; 71(6): 3357–3360.
2. Hatz RA, Brooks WP, Kramling HJ, and Enders G. Stomach immunology and Helicobacter pylori infection. *Current Opinion in Gastroenterology*. 1992;8: 993–1001.
3. Taub DD and Oppenheim JJ. Review of the chemokine meeting “The Third International Symposium of Chemotactic Cytokines.”, *Cytokine*. 1993; 5:175–179.
4. Whicher JT and Evans SW. Cytokines in disease. *Clinical chemistry*. 1990;36(7): 1269-1281.
5. Yuan A, Chen JJ, Yao PL, Yang PC. The role of interleukin-8 in cancer cells and microenvironment interaction. *Frontiers in Bioscience*. 2005; 10: 853-865.
6. Taguchi A, Ohmiya N, Shirai K, Mabuchi N, Itoh A, Hirooka Yet al. Interleukin-8 Promoter Polymorphism Increases the Risk of Atrophic Gastritis and Gastric Cancer in Japan, *Cancer Epidemiology, Biomarkers & Prevention*, A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2005; 14 (11 Pt 1): 2487–2493.
7. Smith MG, Hold GH, Mowat NA, McColl KE, El-Omar EM. The IL-8-251 promoter polymorphism is associated with high IL-8 production, severe inflammation, and increased risk of pre-malignant changes in *H. pylori* positive subjects. *Gut*. 2005; 53(4), A23-A23.
8. Beales IL and Calam J. Stimulation of IL-8 production in human gastric epithelial cells by Helicobacter pylori, IL-1 β and TNF- α requires tyrosine kinase activity, but not protein kinase C, *Cytokine*. 1997; 9: 514-520
9. Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional expression of a human interleukin-8 receptor, *Science*. 1991;253: 1278-1280.
10. Kuai WX, Wang Q, Yang XZ, Zhao Y, Yu R, Tang XJ. Interleukin-8 associates with adhesion, migration, invasion and chemosensitivity of human gastric cancer cells, *World Journal of Gastroenterology*. 2012;18: 979-985.
11. Lee KE, Khoi PN, Xia Y, Park JS, Joo YE, Kim KK et al. Helicobacter pylori and interleukin-8 in gastric cancer, *World Journal of Gastroenterology*. 2013;19(45): 8192–8202.
12. Handa O, Naito Y, Yoshikawa T. Redox biology and gastric carcinogenesis: the role of Helicobacter pylori, *Redox Report*. 2011; 16: 1-7
13. Park KJ, Lee CH, Kim A, Jeong KJ, Kim CH, Kim YS. Death Receptors 4 and 5 Activate Nox1 NADPH Oxidase through Riboflavin Kinase to Induce Reactive Oxygen Species-mediated Apoptotic Cell Death, *The Journal of Biological Chemistry*. 2012;287(5): 3313–3325.
14. Tominaga K, Kawahara T, Sano T, Toida K, Kuwano Y, Sasaki H et al. Evidence for cancer-associated expression of NADPH oxidase 1 (Nox1)-based oxidase system in the human stomach, *Free Radical Biology & Medicine*. 2007;43: 1627-1638.
15. Kim EJ, Lee JR, Chung WC, Jung SH, Sung HJ, Lee YW et al. Association between genetic polymorphisms of NOD 1 and Helicobacter pylori induced gastric mucosal inflammation in healthy Korean population, *Helicobacter*. 2013; 18: 143-150.
16. Rieder G, Hatz RA, Moran AP, Walz A, Stolte M. Role of Adherence in Interleukin-8 Induction in Helicobacter pylori -Associated Gastritis, *Infection and Immunity*. 1997;65(9): 3622-3630.
17. Nomura AM, Perez-Perez GI, Lee J, Stemmermann G, Blaser MJ. Relation between Helicobacter pylori cagA status and risk of peptic ulcer disease. *American Journal of Epidemiology*. 2002;155: 1054-1059.
18. Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach, *Cancer Research*. 1995; 55: 2111-2115
19. Lamb A& Chen LF. The many roads traveled by Helicobacter pylori to NF κ B activation. *Gut Microbes*. 2010;1: 109-113.
20. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. *Annu Review of Physiology*. 1998; 60: 619-642.
21. Peek RM& Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas, *Nature Reviews Cancer*. 2002;2: 28-37.
22. Naumann M and Crabtree JE. Helicobacter pylori-induced epithelial cell signalling in gastric carcinogenesis, *Trends in Microbiology*. 2004;12(1): 29-36.

23. Alber T. Signaling mechanisms of the Mycobacterium tuberculosis receptor Ser/Thr protein kinases, *Current Opinion in Structural Biology*. 2009; 19: 650-657.
24. Allison CC, Kufer TA, Kremmer E, Kaparakis M, Ferrero RL. Helicobacter pylori induces MAPK phosphorylation and AP-1 activation via a NOD1-dependent mechanism, *The Journal of Immunology*. 2009; 183: 8099-8109.
25. Manna SK, Mukhopadhyay A, Bharat B, Alerts E. Resveratrol Suppresses TNF-Induced Activation of Nuclear Transcription Factors NF- κ B, Activator Protein-1, and Apoptosis: Potential Role of Reactive Oxygen, Intermediates and Lipid Peroxidation, *The Journal of Immunology*. 2000; 164 : 6509-6519.
26. Wang YC & Huang KM. In vitro anti-inflammatory effect of apigenin in the Helicobacter pylori-infected gastric adenocarcinoma cells, *Food & Chemical Toxicology*. 2013; 53: 376-383.
27. Jang SH, Cho S, Lee ES, Kim JM, Kim H. The phenyl-thiophenyl propenone RK-I-123 reduces the levels of reactive oxygen species and suppresses the activation of NF- κ B and AP-1 and IL-8 expression in Helicobacter pylori-infected gastric epithelial AGS cells, *Inflammation Research*. 2013; 62: 689-696.
28. Ko SH, Yoo DY, Kim YJ, Choi SM, Kang KK, Kim H et al. A mechanism for the action of the compound DA-6034 on NF- κ B pathway activation in Helicobacter pylori-infected gastric epithelial cells, *Scandinavian Journal of Immunology*. 2011; 74: 253-263.
29. Kang DW, Hwang WC, Park MH, Ko GH, Ha WS, Kim KS et al. Rebamipide abolishes Helicobacter pylori CagA-induced phospholipase D1 expression via inhibition of NF κ B and suppresses invasion of gastric cancer cells, *Oncogene*. 2013; 32: 3531-3542.
30. Kishida O, Miyazaki Y, Murayama Y, Ogasa M, Miyazaki T, Yamamoto T et al. Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells, *Cancer Chemotherapy and Pharmacology*. 2005; 55: 584-594.
31. Zhou C, Ma FZ, Deng XJ, Yuan H, Ma HS. Lactobacilli inhibit interleukin-8 production induced by Helicobacter pylori lipopolysaccharide-activated Toll-like receptor 4, *World Journal of Gastroenterology*. 2008; 14: 50.
32. Liu Z, Xiao B, Tang B, Li B, Li N, Zhu E. Up-regulated microRNA-146a negatively modulate Helicobacter pylori-induced inflammatory response in human gastric epithelial cells, *Microbes and Infection*. 2010; 12: 854-863.